DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.42
-0.35 (-5.17%)
Apr 1, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
345.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 170.16M |
| Autolus Therapeutics | 75.39M |
| Enanta Pharmaceuticals | 66.98M |
| Invivyd | 53.43M |
| XOMA Royalty | 52.15M |
| X4 Pharmaceuticals | 35.11M |
| Armata Pharmaceuticals | 4.90M |
DMAC News
- 1 day ago - DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
- 3 days ago - Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
- 9 days ago - DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - Business Wire
- 27 days ago - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Business Wire
- 5 weeks ago - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
- 2 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire